Amedeo Smart

Free Medical Literature Service


 

Amedeo

Dermatology

  Free Subscription

Articles published in
Cancer
    June 2024
  1. YABROFF KR, Mittu K, Halpern MT
    Cost-of-care discussions for individuals with advanced non-small cell lung cancer and melanoma: Findings from a large, population-based pilot study.
    Cancer. 2024 Jun 13. doi: 10.1002/cncr.35380.
    >> Share

  2. CZARNECKA AM, Ostaszewski K, Blonski PJ, Szumera-Cieckiewicz A, et al
    Long-term efficacy of neoadjuvant-adjuvant targeted therapy in borderline resectable stage IIIB-D and IV melanoma.
    Cancer. 2024 Jun 6. doi: 10.1002/cncr.35425.
    >> Share

    April 2024
  3. KHATTAK MA, Luke JJ
    Top advances of the year: Melanoma.
    Cancer. 2024 Apr 29. doi: 10.1002/cncr.35354.
    >> Share

  4. STERPETTI AV, Gabriele R, Iannone I, Dimarzo L, et al
    National organized screening programs for breast, colorectal, and cervical cancer reduce socioeconomic disparities, but it is not enough.
    Cancer. 2024 Apr 20. doi: 10.1002/cncr.35335.
    >> Share

  5. RUAN Y, Heer E, Brenner DR
    Reply to "National organized screening programs for breast, colorectal, and cervical cancer reduce socioeconomic disparities, but it is not enough".
    Cancer. 2024 Apr 20. doi: 10.1002/cncr.35339.
    >> Share

  6. VANNIER AGL, Dhungana A, Zhao F, Chen N, et al
    Validation of the RSClin risk calculator in the National Cancer Data Base.
    Cancer. 2024;130:1210-1220.
    >> Share

  7. NIERENGARTEN MB
    Routine estradiol testing recommended for women at high risk of breast cancer.
    Cancer. 2024;130:1014.
    >> Share

  8. NIERENGARTEN MB
    Cardiotoxicity of breast cancer drugs requires additional monitoring.
    Cancer. 2024;130:1013-1014.
    >> Share

  9. DELEIRE T, Mitchell JM, De La Cruz L, Isaacs C, et al
    Nonclinical factors associated with the treatment of older women with newly diagnosed low-grade ductal carcinoma in situ.
    Cancer. 2024;130:1041-1051.
    >> Share

    March 2024
  10. WANG X, O'Regan RM
    Breast cancer therapy in China: Introducing the Special Collection.
    Cancer. 2024 Mar 25. doi: 10.1002/cncr.35288.
    >> Share

  11. NIERENGARTEN MB
    FDA approves capivasertib with fulvestrant for breast cancer.
    Cancer. 2024;130:835-836.
    >> Share

  12. WU J, Wang W, Gao L, Shao X, et al
    Cyclin-dependent kinase inhibitors enhance programmed cell death protein 1 immune checkpoint blockade efficacy in triple-negative breast cancer by affecting the immune microenvironment.
    Cancer. 2024 Mar 14. doi: 10.1002/cncr.35270.
    >> Share

  13. ROSENBERG SM, McCue S, He J, Lafky JM, et al
    Alliance A151945: Accrual and characteristics of adolescent and young adult patients in Alliance trials from 2000 to 2017.
    Cancer. 2024;130:750-769.
    >> Share

  14. ZHENG Q, Yan H, He Y, Wang J, et al
    An ultrasound-based nomogram for predicting axillary node pathologic complete response after neoadjuvant chemotherapy in breast cancer: Modeling and external validation.
    Cancer. 2024 Mar 1. doi: 10.1002/cncr.35248.
    >> Share

    February 2024
  15. HOU X, Li X, Han Y, Xu H, et al
    Triple-negative breast cancer survival prediction using artificial intelligence through integrated analysis of tertiary lymphoid structures and tumor budding.
    Cancer. 2024 Feb 29. doi: 10.1002/cncr.35261.
    >> Share

  16. VERSLUIS MAJ, Raijmakers NJH, Baars A, van den Beuken-van Everdingen MHJ, et al
    Trajectories of health-related quality of life and symptom burden in patients with advanced cancer towards the end of life: Longitudinal results from the eQuiPe study.
    Cancer. 2024;130:609-617.
    >> Share

  17. LI X, Luo S, Fu W, Huang M, et al
    Discovery of a proliferation essential gene signature and actin-like 6A as potential biomarkers for predicting prognosis and neoadjuvant chemotherapy response in triple-positive breast cancer.
    Cancer. 2024 Feb 15. doi: 10.1002/cncr.35228.
    >> Share

  18. NGUYEN SM, Tran HTT, Long J, Shrubsole MJ, et al
    Gut microbiome in association with chemotherapy-induced toxicities among patients with breast cancer.
    Cancer. 2024 Feb 6. doi: 10.1002/cncr.35229.
    >> Share

  19. ZIJLKER LP, Levy S, Wolters W, van Thienen JV, et al
    Avelumab treatment for patients with metastatic Merkel cell carcinoma can be safely stopped after 1 year and a PET/CT-confirmed complete response.
    Cancer. 2024;130:433-438.
    >> Share

    January 2024
  20. XIONG W, Xu T, Liu X, Zhang L, et al
    Efficacy and safety of nanoparticle albumin-bound paclitaxel in taxane-pretreated metastatic breast cancer patients.
    Cancer. 2024 Jan 25. doi: 10.1002/cncr.35206.
    >> Share

  21. QU F, Lu R, Liu Q, Wu X, et al
    Antibody-drug conjugates transform the outcome of individuals with low-HER2-expression advanced breast cancer.
    Cancer. 2024 Jan 25. doi: 10.1002/cncr.35205.
    >> Share

  22. SMITH KL, Zhao F, Mayer IA, Tevaarwerk AJ, et al
    Adjuvant platinum versus capecitabine for residual, invasive, triple-negative breast cancer: Patient-reported outcomes in ECOG-ACRIN EA1131.
    Cancer. 2024 Jan 18. doi: 10.1002/cncr.35187.
    >> Share

  23. WANG J, Xia YC, Tian BX, Li JT, et al
    Novel quantitative immunohistochemistry method using histone H3, family 3B as the internal reference standard for measuring human epidermal growth factor receptor 2 expression in breast cancer.
    Cancer. 2024 Jan 13. doi: 10.1002/cncr.35176.
    >> Share

  24. VAN NOT OJ, van den Eertwegh AJM, Haanen JB, van Rijn RS, et al
    BRAF/MEK inhibitor rechallenge in advanced melanoma patients.
    Cancer. 2024 Jan 10. doi: 10.1002/cncr.35178.
    >> Share

  25. ZHOU X, Liu M, Zheng Z, Cao X, et al
    Nomogram predicts survival and surgical benefits for patients with breast cancer with initial bone metastasis: A population-based study.
    Cancer. 2024 Jan 10. doi: 10.1002/cncr.35166.
    >> Share

  26. LIANG X, Zhang L, Gui X, Di L, et al
    Real-world study of palbociclib combined with endocrine therapy for patients with metastatic breast cancer: A comparison of subsequent treatment patterns and HER2 expression analysis.
    Cancer. 2024 Jan 10. doi: 10.1002/cncr.35174.
    >> Share

  27. AGGARWAL A, Han L, Lewis D, Costigan J, et al
    Association of travel time, patient characteristics, and hospital quality with patient mobility for breast cancer surgery: A national population-based study.
    Cancer. 2024 Jan 8. doi: 10.1002/cncr.35153.
    >> Share

  28. SATHISHKUMAR K, Sankarapillai J, Mathew A, Nair RA, et al
    Breast cancer survival in India across 11 geographic areas under the National Cancer Registry Programme.
    Cancer. 2024 Jan 6. doi: 10.1002/cncr.35188.
    >> Share

  29. BHATT R, van den Hout A, Antoniou AC, Shah M, et al
    Estimation of age of onset and progression of breast cancer by absolute risk dependent on polygenic risk score and other risk factors.
    Cancer. 2024 Jan 4. doi: 10.1002/cncr.35183.
    >> Share

  30. PRINSLOO S, Kaptchuk TJ, De Ridder D, Lyle R, et al
    Brain-computer interface relieves chronic chemotherapy-induced peripheral neuropathy: A randomized, double-blind, placebo-controlled trial.
    Cancer. 2024;130:300-311.
    >> Share

    December 2023
  31. EOM KY, Koroukian SM, Dong W, Kim U, et al
    Accounting for Medicaid expansion and regional policy and programs to advance equity in cancer prevention in the United States.
    Cancer. 2023;129:3915-3927.
    >> Share

  32. AKKOC MUSTAFAYEV FN, Shukla MA, Lanier A, Milton DR, et al
    Survival outcomes of patients with HER2/neu-positive breast cancer with germline BRCA mutations.
    Cancer. 2023 Dec 15. doi: 10.1002/cncr.35159.
    >> Share

  33. ZHANG S, Guo L, Zhang Z, Liu X, et al
    Type-I protein arginine methyltransferase inhibition primes anti-programmed cell death protein 1 immunotherapy in triple-negative breast cancer.
    Cancer. 2023 Dec 11. doi: 10.1002/cncr.35142.
    >> Share

    November 2023
  34. WILLIAMS AD, Ruth K, Shaikh SS, Vasigh M, et al
    Should patients with hormone receptor-positive, HER2-negative breast cancer and one or two positive sentinel nodes undergo axillary dissection to determine candidacy for adjuvant abemaciclib?
    Cancer. 2023 Nov 29. doi: 10.1002/cncr.35136.
    >> Share

  35. GORDON MJ, Feng L, Strati P, Lee HJ, et al
    Safety and efficacy of ibrutinib in combination with rituximab and lenalidomide in previously untreated follicular and marginal zone lymphoma: An open label, phase 2 study.
    Cancer. 2023 Nov 20. doi: 10.1002/cncr.35114.
    >> Share

  36. OZTEKIN S, Hooning MJ, van Deurzen CHM, Dietvorst AHP, et al
    The effect of (neo)adjuvant chemotherapy on long-term survival outcomes in patients with invasive lobular breast cancer treated with endocrine therapy: A retrospective cohort study.
    Cancer. 2023 Nov 20. doi: 10.1002/cncr.35125.
    >> Share

  37. JI J, Bae M, Sun CL, Wildes TM, et al
    Falls prechemotherapy and toxicity-related hospitalization during adjuvant chemotherapy for breast cancer in older women: Results from the prospective multicenter HOPE trial.
    Cancer. 2023 Nov 14. doi: 10.1002/cncr.35105.
    >> Share

  38. GALI K, Orban E, Ozga AK, Mohl A, et al
    Does breast cancer modify the long-term relationship between lifestyle behaviors and mortality? A prospective analysis of breast cancer survivors and population-based controls.
    Cancer. 2023 Nov 11. doi: 10.1002/cncr.35104.
    >> Share

  39. YU T, Lu Y, Fang J, Jiang X, et al
    Chimeric antigen receptor-based immunotherapy in breast cancer: Recent progress in China.
    Cancer. 2023 Nov 11. doi: 10.1002/cncr.35096.
    >> Share

  40. LIN M, Luo T, Jin Y, Zhong X, et al
    HER2-low heterogeneity between primary and paired recurrent/metastatic breast cancer: Implications in treatment and prognosis.
    Cancer. 2023 Nov 7. doi: 10.1002/cncr.35101.
    >> Share

  41. LI J, Jiang Z
    Antibody drug conjugates in breast cancer in China: Highlights, challenges, and prospects.
    Cancer. 2023 Nov 3. doi: 10.1002/cncr.35093.
    >> Share

  42. ZHU J, Wang L, Gong W, Li X, et al
    Development and evaluation of a risk assessment tool for the personalized screening of breast cancer in Chinese populations: A prospective cohort study.
    Cancer. 2023 Nov 2. doi: 10.1002/cncr.35095.
    >> Share

    October 2023
  43. SOROURI K, Sella T, Rosenberg SM, Loucks M, et al
    Conception and pregnancy among women with a live birth after breast cancer treatment: A survey study of young breast cancer survivors.
    Cancer. 2023 Oct 25. doi: 10.1002/cncr.35066.
    >> Share

  44. LI Y, Cao J, Wang J, Wu W, et al
    Association of the m(6) A reader IGF2BP3 with tumor progression and brain-specific metastasis in breast cancer.
    Cancer. 2023 Oct 20. doi: 10.1002/cncr.35048.
    >> Share

  45. WHITE RL JR, Wallander ML, Leighliter ME, Sha W, et al
    Assessing trends in breast care surveillance metrics after implementing surgeon-specific tracking and performance reporting in a large, integrated cancer network.
    Cancer. 2023;129:3230-3238.
    >> Share

  46. WILSON BE, Desnoyers A, Nadler MB, Amir E, et al
    Differential treatment effect between younger and older adults for new cancer therapies in solid tumors supporting US Food and Drug Administration approval between 2010 and 2021.
    Cancer. 2023;129:3318-3325.
    >> Share

  47. NIERENGARTEN MB
    First person profile: Jedd Wolchok, MD: Advances in treating metastatic melanoma can, in part, be charted by the career of Dr Wolchok, who was on the front lines of investigating immunotherapy science and developed the first immunologic agents to trea
    Cancer. 2023;129:3190-3191.
    >> Share

  48. KUDIARASU C, Lopez P, Galvao DA, Newton RU, et al
    What are the most effective exercise, physical activity and dietary interventions to improve body composition in women diagnosed with or at high-risk of breast cancer? A systematic review and network meta-analysis.
    Cancer. 2023 Oct 3. doi: 10.1002/cncr.35043.
    >> Share

  49. LEE J, Park S, Jung HA, Lee SH, et al
    A phase 2 multicenter study of docetaxel-PM and trastuzumab-pkrb combination therapy in recurrent or metastatic salivary gland carcinomas.
    Cancer. 2023;129:2966-2974.
    >> Share

    September 2023
  50. EROGLU Z, Chen YA, Smalley I, Li J, et al
    Combined BRAF, MEK, and heat-shock protein 90 (HSP90) inhibition in advanced BRAF V600-mutant melanoma.
    Cancer. 2023 Sep 30. doi: 10.1002/cncr.35029.
    >> Share

  51. SMEDSLAND SK, Falk RS, Reinertsen KV, Kiserud CE, et al
    Burden of late effects in a nationwide sample of long-term breast cancer survivors.
    Cancer. 2023 Sep 30. doi: 10.1002/cncr.35019.
    >> Share

  52. MITCHELL JM, DeLeire T, Isaacs C
    Adherence to hormonal therapy after surgery among older women with ductal carcinoma in situ: Implications for breast cancer-related adverse health events.
    Cancer. 2023 Sep 26. doi: 10.1002/cncr.35009.
    >> Share

  53. SHEN S, Chen Y, Carpio A, Chang C, et al
    Incidence, risk factors, and management of alpelisib-associated hyperglycemia in metastatic breast cancer.
    Cancer. 2023 Sep 25. doi: 10.1002/cncr.34928.
    >> Share

  54. MALCOMSON FC, Wiggins C, Parra-Soto S, Ho FK, et al
    Adherence to the 2018 World Cancer Research Fund/American Institute for Cancer Research Cancer Prevention Recommendations and cancer risk: A systematic review and meta-analysis.
    Cancer. 2023;129:2655-2670.
    >> Share

  55. GANGULY AP, Baker KK, Redman MW, McClintock AH, et al
    Racial disparities in the screening mammography continuum within a heterogeneous health care system.
    Cancer. 2023;129.
    >> Share

  56. NYROP KA, Kelly EA, Teal R, Muss HB, et al
    Clinician perspectives on patient-centered conversations about weight management with patients with early breast cancer.
    Cancer. 2023;129.
    >> Share

  57. PADAMSEE TJ, Stover DG, Tarver WL, Washington CM, et al
    Turning the Page on Breast Cancer in Ohio: Lessons learned from implementing a multilevel intervention to reduce breast cancer mortality among Black women.
    Cancer. 2023;129.
    >> Share

  58. GLASER KM, Dauphin C, Johnson D, Harris N, et al
    Advancing community-academic partnerships to achieve breast health equity: Applying the community-based participatory model to build capacity for sustained impact.
    Cancer. 2023;129.
    >> Share

  59. KO NY, Fikre TG, Buck AK, Restrepo E, et al
    Breast cancer survivorship experiences among Black women.
    Cancer. 2023;129.
    >> Share

  60. BEA VJ, An A, Gordon AM, Antoine FS, et al
    Mammography screening beliefs and barriers through the lens of Black women during the COVID-19 pandemic.
    Cancer. 2023;129.
    >> Share

    August 2023
  61. SARA G, Lambeth C, Burgess P, Curtis J, et al
    Breast screening participation and degree of spread of invasive breast cancer at diagnosis in mental health service users, a population linkage study.
    Cancer. 2023 Aug 26. doi: 10.1002/cncr.35002.
    >> Share

  62. KWAN ML, Valice E, Ergas IJ, Roh JM, et al
    Alcohol consumption and prognosis and survival in breast cancer survivors: The Pathways Study.
    Cancer. 2023 Aug 9. doi: 10.1002/cncr.34972.
    >> Share

  63. MALMGREN JA, Atwood MK, Kaplan HG
    Persistence of patient-detected breast cancer over time: 1990-2019.
    Cancer. 2023 Aug 8. doi: 10.1002/cncr.34973.
    >> Share

    July 2023
  64. WIESE D, Stroup AM, Islami F, Mattes M, et al
    Geographic diffusion of digital mammography in the United States.
    Cancer. 2023;129:2144-2151.
    >> Share

  65. MOORADIAN MJ, Sullivan RJ
    The case for adjuvant BRAF-targeted therapy versus adjuvant anti-PD-1 therapy for patients with resected, high-risk melanoma.
    Cancer. 2023;129:2117-2121.
    >> Share

  66. NIERENGARTEN MB
    Neoadjuvant immunotherapy improves outlook in high-risk melanoma.
    Cancer. 2023;129:1952.
    >> Share

    June 2023
  67. DEMKOWICZ P, Pointdujour-Lim R, Miguez S, Lee Y, et al
    Determinants of overall survival in patients with metastatic uveal melanoma.
    Cancer. 2023 Jun 29. doi: 10.1002/cncr.34927.
    >> Share

  68. ROY AM, Kumarasamy VM, Dhakal A, O'Regan R, et al
    A review of treatment options in HER2-low breast cancer and proposed treatment sequencing algorithm.
    Cancer. 2023 Jun 22. doi: 10.1002/cncr.34904.
    >> Share

  69. SPRAGUE BL, Ichikawa L, Eavey J, Lowry KP, et al
    Breast cancer risk characteristics of women undergoing whole-breast ultrasound screening versus mammography alone.
    Cancer. 2023 Jun 12. doi: 10.1002/cncr.34768.
    >> Share

  70. FARVID MS, Spence ND, Rosner BA, Barnett JB, et al
    Associations of low-carbohydrate diets with breast cancer survival.
    Cancer. 2023 Jun 10. doi: 10.1002/cncr.34819.
    >> Share

  71. PLEASANT VA, Purkiss AS, Merjaver SD
    Redefining the "crown": Approaching chemotherapy-induced alopecia among Black patients with breast cancer.
    Cancer. 2023;129:1629-1633.
    >> Share

  72. RENTSCHER KE, Bethea TN, Zhai W, Small BJ, et al
    Epigenetic aging in older breast cancer survivors and non-cancer controls: preliminary findings from the Thinking and Living with Cancer (TLC) Study.
    Cancer. 2023 Jun 1. doi: 10.1002/cncr.34818.
    >> Share

    May 2023
  73. THOMAS TH, Bender C, Donovan HS, Murray PJ, et al
    The feasibility, acceptability, and preliminary efficacy of a self-advocacy serious game for women with advanced breast or gynecologic cancer.
    Cancer. 2023 May 27. doi: 10.1002/cncr.34887.
    >> Share

  74. MANDELBLATT JS, Ruterbusch JJ, Thompson HS, Zhou X, et al
    Association between major discrimination and deficit accumulation in African American cancer survivors: The Detroit Research on Cancer Survivors Study.
    Cancer. 2023;129:1557-1568.
    >> Share

  75. LU X, He M, Yu L, Gou Z, et al
    Is repeat sentinel lymph node biopsy possible for surgical axillary staging among patients with ipsilateral breast tumor recurrence?
    Cancer. 2023;129:1492-1501.
    >> Share

  76. SPENCER JC, Noel L, Shokar NK, Pignone MP, et al
    Understanding the role of access in Hispanic cancer screening disparities.
    Cancer. 2023;129:1569-1578.
    >> Share

  77. PATUZZO R, Mattavelli I, Gallino G, Galeone C, et al
    The prognostic role of mitotic rate in cutaneous malignant melanoma: Evidence from a multicenter study on behalf of the Italian Melanoma Intergroup.
    Cancer. 2023 May 10. doi: 10.1002/cncr.34824.
    >> Share

  78. GERSHENWALD JE
    Mitotic rate in primary cutaneous melanoma: Cell division matters.
    Cancer. 2023 May 10. doi: 10.1002/cncr.34825.
    >> Share

    April 2023
  79. LEHRER S, Rheinstein PH
    Increased survival of women with luminal breast cancer and progesterone receptor immunohistochemical expression of greater than 10.
    Cancer. 2023 Apr 27. doi: 10.1002/cncr.34828.
    >> Share

  80. LASHEN AG, Toss MS, Rakha EA
    Reply to "Increased survival of women with luminal breast cancer and progesterone receptor immunohistochemical expression of greater than 10%".
    Cancer. 2023 Apr 27. doi: 10.1002/cncr.34826.
    >> Share

  81. MANDELBLATT JS, Small BJ, Zhou X, Nakamura ZM, et al
    Plasma levels of interleukin-6 mediate neurocognitive performance in older breast cancer survivors: The Thinking and Living With Cancer study.
    Cancer. 2023 Apr 25. doi: 10.1002/cncr.34784.
    >> Share

  82. CONROY SM, Von Behren J, Kwan ML, Kushi LH, et al
    Neighborhood attributes and cardiovascular disease risk in breast cancer survivors: The Pathways Study.
    Cancer. 2023 Apr 25. doi: 10.1002/cncr.34794.
    >> Share

  83. GALUS L, Michalak M, Lorenz M, Stoinska-Swiniarek R, et al
    Vitamin D supplementation increases objective response rate and prolongs progression-free time in patients with advanced melanoma undergoing anti-PD1 therapy.
    Cancer. 2023 Apr 24. doi: 10.1002/cncr.34718.
    >> Share

  84. KOIZUMI T, Sugishita Y, Suzuki-Takahashi Y, Nara K, et al
    Oncofertility-related psycho-educational therapy for young adult patients with breast cancer and their partners: randomized controlled trial.
    Cancer. 2023 Apr 21. doi: 10.1002/cncr.34796.
    >> Share

  85. LEI F, Vanderpool RC, McLouth LE, Romond EH, et al
    Influence of depression on breast cancer treatment and survival: A Kentucky population-based study.
    Cancer. 2023 Apr 17. doi: 10.1002/cncr.34676.
    >> Share

  86. LIGIBEL JA, Zheng Y, Barry WT, Sella T, et al
    Effects of an educational physical activity intervention in young women with newly diagnosed breast cancer: Findings from the Young and Strong Study.
    Cancer. 2023 Apr 5. doi: 10.1002/cncr.34779.
    >> Share

  87. SAAVEDRA C, Gion M, Cortes J, Llombart-Cussac A, et al
    Top advances of the year: Breast cancer.
    Cancer. 2023 Apr 4. doi: 10.1002/cncr.34752.
    >> Share

  88. NELSON BE, Saleem S, Damodaran S, Somaiah N, et al
    Phase 1b study of combined selinexor and eribulin for the treatment of advanced solid tumors and triple-negative breast cancer.
    Cancer. 2023 Apr 4. doi: 10.1002/cncr.34773.
    >> Share

  89. TRAPANI D, Mayer EL
    What's the reality for CDK4/6 inhibitors: Clinical trials or real-world evidence?
    Cancer. 2023;129:986-988.
    >> Share

    March 2023
  90. LEV-ARI S, Serzan M, Wu T, Ip A, et al
    The impact of immunosuppressive agents on immune checkpoint inhibitor efficacy in patients with advanced melanoma: A real-world, multicenter, retrospective study.
    Cancer. 2023 Mar 23. doi: 10.1002/cncr.34742.
    >> Share

  91. WEISS A, Martinez-Saez O, Waks AG, Laws A, et al
    Nodal positivity and systemic therapy among patients with clinical T1-T2N0 human epidermal growth factor receptor-positive breast cancer: Results from two international cohorts.
    Cancer. 2023 Mar 23. doi: 10.1002/cncr.34750.
    >> Share

  92. MORRELL BL, Morrell MB, Ball JA, Ochoa AC, et al
    Disparities in the use of screening breast magnetic resonance imaging persist in Louisiana after the Affordable Care Act: A question of access, policy, institutional support, or something else?
    Cancer. 2023;129:829-833.
    >> Share

  93. METCALFE KA, Gronwald J, Tung NM, McCuaig JM, et al
    The risks of cancer in older women with BRCA pathogenic variants: How far have we come?
    Cancer. 2023;129:901-907.
    >> Share

  94. NEUMAN HB, Schumacher JR, Edge SB, Ruddy KJ, et al
    The influence of anatomic stage and receptor status on first recurrence for breast cancer within 5 years (AFT-01).
    Cancer. 2023 Mar 6. doi: 10.1002/cncr.34656.
    >> Share

  95. EROGLU Z, Krinshpun S, Kalashnikova E, Sudhaman S, et al
    Circulating tumor DNA-based molecular residual disease detection for treatment monitoring in advanced melanoma patients.
    Cancer. 2023 Mar 4. doi: 10.1002/cncr.34716.
    >> Share

    February 2023
  96. HYDE ET, LaCroix AZ, Evenson KR, Howard AG, et al
    Accelerometer-measured physical activity and postmenopausal breast cancer incidence in the Women's Health Accelerometry Collaboration.
    Cancer. 2023 Feb 22. doi: 10.1002/cncr.34699.
    >> Share

  97. ALLEN PB, McCook-Veal AA, Switchenko JM, Paulino DM, et al
    Staging lymph nodes and blood at diagnosis in mycosis fungoides identifies patients at increased risk of progression to advanced stage: A retrospective cohort study.
    Cancer. 2023;129:541-550.
    >> Share

  98. LOWRY KP, Ichikawa L, Hubbard RA, Buist DSM, et al
    Variation in second breast cancer risk after primary invasive cancer by time since primary cancer diagnosis and estrogen receptor status.
    Cancer. 2023 Feb 15. doi: 10.1002/cncr.34679.
    >> Share

  99. GOYAL RK, Chen H, Abughosh SM, Holmes HM, et al
    Overall survival associated with CDK4/6 inhibitors in patients with HR+/HER2- metastatic breast cancer in the United States: A SEER-Medicare population-based study.
    Cancer. 2023 Feb 9. doi: 10.1002/cncr.34675.
    >> Share


  100. Collagen type XII linked with poor overall survival in breast cancer.
    Cancer. 2023;129:331-332.
    >> Share

    January 2023
  101. REEDER-HAYES KE, Jackson BE, Baggett CD, Kuo TM, et al
    Race, geography, and risk of breast cancer treatment delays: A population-based study 2004-2015.
    Cancer. 2023 Jan 23. doi: 10.1002/cncr.34573.
    >> Share

  102. JIN J, Cao J, Li B, Li T, et al
    Landscape of DNA damage response gene alterations in breast cancer: A comprehensive investigation.
    Cancer. 2023 Jan 18. doi: 10.1002/cncr.34618.
    >> Share

  103. LASHEN AG, Toss MS, Mongan NP, Green AR, et al
    The clinical value of progesterone receptor expression in luminal breast cancer: A study of a large cohort with long-term follow-up.
    Cancer. 2023 Jan 18. doi: 10.1002/cncr.34655.
    >> Share

  104. WIN TS, Tsao H
    Keratinocytic skin cancers-Update on the molecular biology.
    Cancer. 2023 Jan 16. doi: 10.1002/cncr.34635.
    >> Share

  105. RAMADAS K, Basu P, Mathew BS, Muwonge R, et al
    Effectiveness of triennial screening with clinical breast examination: 14-years follow-up outcomes of randomized clinical trial in Trivandrum, India.
    Cancer. 2023;129:272-282.
    >> Share

  106. LICAJ I, Coquan E, Dabakuyo-Yonli TS, Dauchy S, et al
    Baseline quality of life and chemotherapy toxicities in patients with early breast cancer.
    Cancer. 2023 Jan 15. doi: 10.1002/cncr.34643.
    >> Share

  107. AUGUSTIN RC, Luke JJ
    Top advances of the year: Melanoma.
    Cancer. 2023 Jan 11. doi: 10.1002/cncr.34590.
    >> Share

  108. MELIS M, Schroyen G, Leenaerts N, Smeets A, et al
    The impact of mindfulness on cancer-related cognitive impairment in breast cancer survivors with cognitive complaints.
    Cancer. 2023 Jan 10. doi: 10.1002/cncr.34640.
    >> Share

  109. PARISE CA, Caggiano V
    The association of race/ethnicity in male breast cancer survival within similar comorbidity cohorts.
    Cancer. 2023 Jan 3. doi: 10.1002/cncr.34592.
    >> Share


  110. Updated ASCO guidelines for patients with HER2-positive breast cancer.
    Cancer. 2023;129:10.
    >> Share

    December 2022
  111. ATKINS SLP, Zimmer AS
    Neurologic complications of breast cancer.
    Cancer. 2022 Dec 20. doi: 10.1002/cncr.34518.
    >> Share

  112. NIERENGARTEN MB
    Molecular insights into triple-negative breast cancer metastasis: Epithelial- mesenchymal transition: There is a need to better understand the molecular drivers behind triple-negative breast cancer to help curb the incidence of metastasis: There is a
    Cancer. 2022;128:4174.
    >> Share

  113. HOPPER JL, Nguyen TL, Li S
    What if the age at which a woman started regular mammographic screening depended on her risk, not age?
    Cancer. 2022;128:4179-4181.
    >> Share

  114. LAVASANI SM, Somlo G, Yost SE, Frankel PH, et al
    Phase 2 prospective open label study of neoadjuvant nab-paclitaxel, trastuzumab, and pertuzumab in patients with HER2-positive primary breast cancer.
    Cancer. 2022 Dec 14. doi: 10.1002/cncr.34589.
    >> Share

    November 2022
  115. GU J, Tong T, Xu D, Cheng F, et al
    Deep learning radiomics of ultrasonography for comprehensively predicting tumor and axillary lymph node status after neoadjuvant chemotherapy in breast cancer patients: A multicenter study.
    Cancer. 2022 Nov 19. doi: 10.1002/cncr.34540.
    >> Share

  116. MALLARD J, Hucteau E, Schott R, Trensz P, et al
    Early skeletal muscle deconditioning and reduced exercise capacity during (neo)adjuvant chemotherapy in patients with breast cancer.
    Cancer. 2022 Nov 17. doi: 10.1002/cncr.34533.
    >> Share


  117. Liquid biopsy prototype assay for breast cancer.
    Cancer. 2022;128:3905.
    >> Share

  118. ZHOU T, Zhang Y, Ma Y, Ma W, et al
    Comparison of aprepitant versus desloratadine for EGFR-TKI-induced pruritus: A randomized phase 2 clinical trial.
    Cancer. 2022;128:3969-3976.
    >> Share

  119. VALLANCE JK, Friedenreich CM, Wang Q, Matthews CE, et al
    Associations of device-measured physical activity and sedentary time with quality of life and fatigue in newly diagnosed breast cancer patients: Baseline results from the AMBER cohort study.
    Cancer. 2022 Nov 11. doi: 10.1002/cncr.34531.
    >> Share

  120. EGUCHI MM, Elder DE, Barnhill RL, Piepkorn MW, et al
    Prognostic modeling of cutaneous melanoma stage I patients using cancer registry data identifies subsets with very-low melanoma mortality.
    Cancer. 2022 Nov 7. doi: 10.1002/cncr.34490.
    >> Share

    October 2022
  121. ELLINGTON TD, Henley SJ, Wilson RJ, Miller JW, et al
    Trends in breast cancer mortality by race/ethnicity, age, and US census region, United States horizontal line 1999-2020.
    Cancer. 2022 Oct 30. doi: 10.1002/cncr.34503.
    >> Share

  122. KRUL IM, Boekel NB, Kramer I, Janus CPM, et al
    Breast cancer and cardiovascular outcomes after breast cancer in survivors of Hodgkin lymphoma.
    Cancer. 2022 Oct 25. doi: 10.1002/cncr.34464.
    >> Share

  123. MUNHOZ RR, Nader-Marta G, de Camargo VP, Queiroz MM, et al
    A phase 2 study of first-line nivolumab in patients with locally advanced or metastatic cutaneous squamous-cell carcinoma.
    Cancer. 2022 Oct 24. doi: 10.1002/cncr.34463.
    >> Share

  124. STEUER CE, Saba NF
    Immune check point inhibitors in advanced cutaneous squamous cell carcinomas: "Repeat and replicate".
    Cancer. 2022 Oct 24. doi: 10.1002/cncr.34465.
    >> Share

  125. DURHAM DD, Abraham LA, Roberts MC, Khan CP, et al
    Breast cancer incidence among women with a family history of breast cancer by relative's age at diagnosis.
    Cancer. 2022 Oct 19. doi: 10.1002/cncr.34365.
    >> Share

  126. GENNARO M, Maccauro M, Mariani L, Listorti C, et al
    Occurrence of breast-cancer-related lymphedema after reverse lymphatic mapping and selective axillary dissection versus standard surgical treatment of axilla: A two-arm randomized clinical trial.
    Cancer. 2022 Oct 19. doi: 10.1002/cncr.34498.
    >> Share

  127. REN Y, Kebede MA, Ogunleye AA, Emerson MA, et al
    Burden of lymphedema in long-term breast cancer survivors by race and age.
    Cancer. 2022 Oct 12. doi: 10.1002/cncr.34489.
    >> Share

  128. WARREN LEG, Niman SM, Remolano MC, Landry JM, et al
    Incidence, characteristics, and management of central nervous system metastases in patients with inflammatory breast cancer.
    Cancer. 2022 Oct 10. doi: 10.1002/cncr.34441.
    >> Share

  129. DHAKAL A, Anders CK
    Screening brain MRI in inflammatory breast cancer: Is it time?
    Cancer. 2022 Oct 10. doi: 10.1002/cncr.34442.
    >> Share

  130. JACOBS JM, Post K, Massad K, Horick NK, et al
    A telehealth intervention for symptom management, distress, and adherence to adjuvant endocrine therapy: A randomized controlled trial.
    Cancer. 2022;128:3541-3551.
    >> Share

  131. COLONNA M, Grosclaude P, Bouvier AM, Goungounga J, et al
    Health status of prevalent cancer cases as measured by mortality dynamics (cancer vs. noncancer): Application to five major cancers sites.
    Cancer. 2022;128:3663-3673.
    >> Share

    September 2022
  132. LI Y, Li WW, Yuan L, Xu B, et al
    Is repeat breast conservation possible for small ipsilateral breast cancer recurrence?
    Cancer. 2022 Sep 20. doi: 10.1002/cncr.34468.
    >> Share

  133. SNYDER RA, Hu CY, DiBrito SR, Chang GJ, et al
    Association of Medicaid expansion with racial disparities in cancer stage at presentation.
    Cancer. 2022;128:3340-3351.
    >> Share

  134. WEISER R, Polychronopoulou E, Klimberg VS
    Reply to "The use of national datasets to evaluate outcomes for invasive lobular carcinoma".
    Cancer. 2022;128:3418-3419.
    >> Share

  135. MARMOR S, Hui JYC, White MJ, Tuttle TM, et al
    The use of national datasets to evaluate outcomes for invasive lobular carcinoma.
    Cancer. 2022;128:3416-3417.
    >> Share

  136. LEONE JP, Hassett MJ, Leone J, Tolaney SM, et al
    Efficacy of neoadjuvant chemotherapy in male breast cancer compared with female breast cancer.
    Cancer. 2022 Sep 7. doi: 10.1002/cncr.34448.
    >> Share

  137. SONDAK VK, Neves RI, Wuthrick EJ, Messina JL, et al
    Current and future approaches in the surgical management of T3b/T4 primary and locoregionally advanced melanoma.
    Cancer. 2022 Sep 6. doi: 10.1002/cncr.34449.
    >> Share

    August 2022
  138. JOHANNET P, Simons M, Qian Y, Azmy N, et al
    Risk and tropism of central nervous system (CNS) metastases in patients with stage II and III cutaneous melanoma.
    Cancer. 2022 Aug 25. doi: 10.1002/cncr.34435.
    >> Share

  139. MAKHNOON S, Chen M, Levin B, Ensinger M, et al
    Use of breast surveillance between women with pathogenic variants and variants of uncertain significance in breast cancer susceptibility genes.
    Cancer. 2022 Aug 23. doi: 10.1002/cncr.34429.
    >> Share

  140. ADIMORA IJ, Wilson NR, Pemmaraju N
    Blastic plasmacytoid dendritic cell neoplasm (BPDCN): A promising future in the era of targeted therapeutics.
    Cancer. 2022;128:3019-3026.
    >> Share

  141. KNERR S, Guo B, Mittendorf KF, Feigelson HS, et al
    Risk-reducing surgery in unaffected individuals receiving cancer genetic testing in an integrated health care system.
    Cancer. 2022;128:3090-3098.
    >> Share

  142. QIU JQ, Zhang WL, Fang X, Cui T, et al
    Survival analysis in a prediction model for early systemic recurrence in breast cancer.
    Cancer. 2022 Aug 15. doi: 10.1002/cncr.34417.
    >> Share

  143. OSAKO T, Matsuura M, Tsuda H, Noguchi S, et al
    Reply to "Survival analysis in a prediction model for early systemic recurrence in breast cancer".
    Cancer. 2022 Aug 15. doi: 10.1002/cncr.34415.
    >> Share

  144. PATEL R, Hovstadius M, Kier MW, Moshier EL, et al
    Correlation of the Ki67 Working Group prognostic risk categories with the Oncotype DX Recurrence Score in early breast cancer.
    Cancer. 2022 Aug 10. doi: 10.1002/cncr.34426.
    >> Share

  145. LEHRER S, Rheinstein PH
    Breast cancer and body weight changes of young women in the UK Biobank cohort.
    Cancer. 2022 Aug 9. doi: 10.1002/cncr.34423.
    >> Share


  146. Trastuzumab deruxtecan beats trastuzumab emtansine in lowered disease progression, death.
    Cancer. 2022;128:2852.
    >> Share


  147. Breast arterial calcification is a risk factor for cardiovascular disease.
    Cancer. 2022;128:2851-2852.
    >> Share


  148. First person profile: Monica Morrow, MD: The chief of the Breast Service at Memorial Sloan Kettering Cancer Center (MSKCC) has made a lasting impact on breast surgical oncology: The chief of the Breast Service at Memorial Sloan Kettering Cancer Center
    Cancer. 2022;128:2850-2851.
    >> Share

  149. LEHRER S, Rheinstein PH
    Neither tamoxifen nor aromatase inhibitors increase the risk of Parkinson disease in the UK Biobank cohort.
    Cancer. 2022;128:2997-2998.
    >> Share

  150. SOLDATO D, Havas J, Crane TE, Presti D, et al
    Coffee and tea consumption, patient-reported, and clinical outcomes in a longitudinal study of patients with breast cancer.
    Cancer. 2022 Aug 1. doi: 10.1002/cncr.34401.
    >> Share

  151. HOXHAJ A, Drissen MMCM, Vos JR, Bult P, et al
    The yield and effectiveness of breast cancer surveillance in women with PTEN Hamartoma Tumor Syndrome.
    Cancer. 2022;128:2883-2891.
    >> Share

    July 2022
  152. BARGON CA, Young-Afat DA, Ikinci M, Braakenburg A, et al
    Breast cancer recurrence after immediate and delayed postmastectomy breast reconstruction-A systematic review and meta-analysis.
    Cancer. 2022 Jul 27. doi: 10.1002/cncr.34393.
    >> Share

  153. MOUBADDER L, Collin LJ, Nash R, Switchenko JM, et al
    Drivers of racial, regional, and socioeconomic disparities in late-stage breast cancer mortality.
    Cancer. 2022 Jul 22. doi: 10.1002/cncr.34391.
    >> Share

  154. KOELMEYER LA, Gaitatzis K, Dietrich MS, Shah CS, et al
    Risk factors for breast cancer-related lymphedema in patients undergoing 3 years of prospective surveillance with intervention.
    Cancer. 2022 Jul 7. doi: 10.1002/cncr.34377.
    >> Share

  155. HYLAND CJ, Manrique OJ, Weiss A, Broyles JM, et al
    Preventive strategies for breast cancer-related lymphedema: Working toward optimal patient selection.
    Cancer. 2022 Jul 7. doi: 10.1002/cncr.34374.
    >> Share

  156. O'ROURKE K
    Breast cancer overdiagnosis through mammograms is lower than previous estimates.
    Cancer. 2022;128:2398-2399.
    >> Share

  157. CASANOVA NL, LeClair AM, Xiao V, Mullikin KR, et al
    Development of a workflow process mapping protocol to inform the implementation of regional patient navigation programs in breast oncology.
    Cancer. 2022;128 Suppl 13:2649-2658.
    >> Share

  158. BATTAGLIA TA, Gunn CM, Bak SM, Flacks J, et al
    Patient navigation to address sociolegal barriers for patients with cancer: A comparative-effectiveness study.
    Cancer. 2022;128 Suppl 13:2623-2635.
    >> Share

  159. CATHCART-RAKE EJ, Sanft T, Tevaarwerk AJ
    Weight gain after breast cancer diagnosis: It's complicated....
    Cancer. 2022 Jul 1. doi: 10.1002/cncr.34343.
    >> Share

  160. SELLA T, Zheng Y, Tan-Wasielewski Z, Rosenberg SM, et al
    Body weight changes and associated predictors in a prospective cohort of young breast cancer survivors.
    Cancer. 2022 Jul 1. doi: 10.1002/cncr.34342.
    >> Share

    June 2022
  161. RAUH-HAIN JA, Zubizarreta J, Nitecki R, Melamed A, et al
    Survival outcomes following pregnancy or assisted reproductive technologies after breast cancer: A population-based study.
    Cancer. 2022 Jun 29. doi: 10.1002/cncr.34371.
    >> Share

  162. WATSON NW, Wander SA, Shatzel JJ, Al-Samkari H, et al
    Venous and arterial thrombosis associated with abemaciclib therapy for metastatic breast cancer.
    Cancer. 2022 Jun 29. doi: 10.1002/cncr.34367.
    >> Share

  163. SITTENFELD SMC, Zabor EC, Hamilton SN, Kuerer HM, et al
    A multi-institutional prediction model to estimate the risk of recurrence and mortality after mastectomy for T1-2N1 breast cancer.
    Cancer. 2022 Jun 17. doi: 10.1002/cncr.34352.
    >> Share

  164. HREBINKO KA, Bryce CL, Downs-Canner S, Diego EJ, et al
    Cost-effectiveness of Choosing Wisely guidelines for axillary observation in women older than age 70 years with hormone receptor-positive, clinically node-negative, operable breast tumors.
    Cancer. 2022;128:2258-2268.
    >> Share

  165. KHOSROW-KHAVAR F, Azoulay L, Montastruc JL, Montastruc F, et al
    Aromatase inhibitors and the incidence of Parkinson disease: A population-based cohort study.
    Cancer. 2022;128:2339-2347.
    >> Share

  166. ALTUNDAG K
    Select cases might get a benefit from chemotherapy for Stage I pT1aN0M0 HER2+ breast cancer.
    Cancer. 2022 Jun 7. doi: 10.1002/cncr.34340.
    >> Share

  167. CAO L, Stabellini N, Amin AL, Montero AJ, et al
    Reply to "Select cases might get a benefit from chemotherapy for Stage I pT1aN0M0 HER2+ breast cancer".
    Cancer. 2022 Jun 7. doi: 10.1002/cncr.34339.
    >> Share

  168. CARROLL JE, Olmstead R, Haque R, Irwin MR, et al
    Accelerated mononuclear cell telomere attrition in breast cancer survivors with depression history: A 2-year longitudinal cohort study.
    Cancer. 2022 Jun 7. doi: 10.1002/cncr.34329.
    >> Share

  169. O'ROURKE K
    Cemiplimab shines for recurrent cervical cancer.
    Cancer. 2022;128:2050-2051.
    >> Share

  170. O'ROURKE K
    Compression sleeves reduce lymphedema after lymph node dissection: In women who had breast cancer surgery to remove their axillary lymph nodes, the sleeves helped prevent arm swelling: In women who had breast cancer surgery to remove their axillary ly
    Cancer. 2022;128:2049-2050.
    >> Share

  171. JOUNG RH, Nelson H, Mullett TW, Kurtzman SH, et al
    A national quality improvement study identifying and addressing cancer screening deficits due to the COVID-19 pandemic.
    Cancer. 2022;128:2119-2125.
    >> Share

  172. HARBECK N, Burstein HJ, Hurvitz SA, Johnston S, et al
    A look at current and potential treatment approaches for hormone receptor-positive, HER2-negative early breast cancer.
    Cancer. 2022;128 Suppl 11:2209-2223.
    >> Share

  173. O'BRIEN KM, Sandler DP
    Reply to "Vitamin D and breast cancer: Stop torturing the data!"
    Cancer. 2022 Jun 1. doi: 10.1002/cncr.34274.
    >> Share

  174. BRAILLON A
    Vitamin D and breast cancer: Stop torturing the data!
    Cancer. 2022 Jun 1. doi: 10.1002/cncr.34272.
    >> Share

    May 2022
  175. KIM G, Pastoriza JM, Qin J, Lin J, et al
    Racial disparity in distant recurrence-free survival in patients with localized breast cancer: A pooled analysis of National Surgical Adjuvant Breast and Bowel Project trials.
    Cancer. 2022 May 17. doi: 10.1002/cncr.34241.
    >> Share

  176. JONES VC, Kruper L, Mortimer J, Ashing KT, et al
    Understanding drivers of the Black:White breast cancer mortality gap: A call for more robust definitions.
    Cancer. 2022 May 17. doi: 10.1002/cncr.34243.
    >> Share

  177. O'ROURKE K
    Relatlimab plus nivolumab beneficial for previously untreated metastatic or unresectable melanoma.
    Cancer. 2022;128:1887.
    >> Share

  178. KORIC A, Chang CP, Mark B, Rowe K, et al
    Cardiovascular disease risk in long-term breast cancer survivors: A population-based cohort study.
    Cancer. 2022 May 13. doi: 10.1002/cncr.34224.
    >> Share

  179. ZHANG Y, Mao X, Yu X, Huang X, et al
    Bone mineral density and risk of breast cancer: A cohort study and Mendelian randomization analysis.
    Cancer. 2022 May 5. doi: 10.1002/cncr.34252.
    >> Share

  180. WEISER R, Polychronopoulou E, Hatch SS, Haque W, et al
    Adjuvant chemotherapy in patients with invasive lobular carcinoma and use of the 21-gene recurrence score: A National Cancer Database analysis.
    Cancer. 2022;128:1738-1747.
    >> Share

  181. LAU-MIN KS, Li Y, Eads JR, Mamtani R, et al
    Association between timely targeted treatment and outcomes in patients with metastatic HER2-overexpressing gastroesophageal adenocarcinoma.
    Cancer. 2022;128:1853-1862.
    >> Share

    April 2022
  182. O'BRIEN KM, Harmon QE, Jackson CL, Diaz-Santana MV, et al
    Vitamin D concentrations and breast cancer incidence among Black/African American and non-Black Hispanic/Latina women.
    Cancer. 2022 Apr 25. doi: 10.1002/cncr.34198.
    >> Share

  183. LIGIBEL JA, Pierce LJ, Bender CM, Crane TE, et al
    Attention to diet, exercise, and weight in oncology care: Results of an American Society of Clinical Oncology national patient survey.
    Cancer. 2022 Apr 20. doi: 10.1002/cncr.34231.
    >> Share

  184. BRUIJNEN CP, Koldenhof JJ, Verheijden RJ, van den Bos F, et al
    Frailty and checkpoint inhibitor toxicity in older patients with melanoma.
    Cancer. 2022 Apr 19. doi: 10.1002/cncr.34230.
    >> Share

  185. O'ROURKE K
    Virginia G. Kaklamani, MD, highlights important news from SABCS: Updates from research on therapies for the treatment of breast cancer show promise: Updates from research on therapies for the treatment of breast cancer show promise.
    Cancer. 2022;128:1557-1558.
    >> Share

  186. ANDERSON BM, White JR
    Improving the well-being of women with ductal carcinoma in situ: A worthy goal with an unclear route to success.
    Cancer. 2022;128:1571-1573.
    >> Share

  187. ROSENBERG SM, Gierisch JM, Revette AC, Lowenstein CL, et al
    "Is it cancer or not?" A qualitative exploration of survivor concerns surrounding the diagnosis and treatment of ductal carcinoma in situ.
    Cancer. 2022;128:1676-1683.
    >> Share

  188. MELKONIAN SC, Jim MA, Pete D, Poel A, et al
    Cancer disparities among non-Hispanic urban American Indian and Alaska Native populations in the United States, 1999-2017.
    Cancer. 2022;128:1626-1636.
    >> Share

  189. HAYATI Z, Montazeri V, Shivappa N, Hebert JR, et al
    The association between the inflammatory potential of diet and the risk of histopathological and molecular subtypes of breast cancer in northwestern Iran: Results from the Breast Cancer Risk and Lifestyle study.
    Cancer. 2022 Apr 7. doi: 10.1002/cncr.34183.
    >> Share

  190. DUVAL A, Davis CG, Khoo EL, Romanow H, et al
    Mindfulness-based stress reduction and cognitive function among breast cancer survivors: A randomized controlled trial.
    Cancer. 2022 Apr 6. doi: 10.1002/cncr.34209.
    >> Share

  191. O'ROURKE K
    Late-day immunotherapy infusions may affect overall survival in patients with melanoma.
    Cancer. 2022;128:1358.
    >> Share

  192. TSURUDA KM, Larsen M, Roman M, Hofvind S, et al
    Cumulative risk of a false-positive screening result: A retrospective cohort study using empirical data from 10 biennial screening rounds in BreastScreen Norway.
    Cancer. 2022;128:1373-1380.
    >> Share

  193. BOROSUND E, Ehlers SL, Clark MM, Andrykowski MA, et al
    Digital stress management in cancer: Testing StressProffen in a 12-month randomized controlled trial.
    Cancer. 2022;128:1503-1512.
    >> Share

  194. CAO L, Towe CW, Shenk R, Stabellini N, et al
    A comparison of local therapy alone with local plus systemic therapy for stage I pT1aN0M0 HER2+ breast cancer: A National Cancer Database analysis.
    Cancer. 2022 Apr 1. doi: 10.1002/cncr.34200.
    >> Share

    March 2022
  195. KARAPETYAN L, Yang X, Knight AD, Huang Z, et al
    Poorer survival outcomes in patients with multiple versus single primary melanoma.
    Cancer. 2022 Mar 23. doi: 10.1002/cncr.34169.
    >> Share

  196. BYCHKOVSKY BL, Lo MT, Yussuf A, Horton C, et al
    Prevalence and spectrum of pathogenic variants among patients with multiple primary cancers evaluated by clinical characteristics.
    Cancer. 2022;128:1275-1283.
    >> Share

  197. BERLIN NL, Abrahamse P, Momoh AO, Katz SJ, et al
    Perceived financial decline related to breast reconstruction following mastectomy in a diverse population-based cohort.
    Cancer. 2022;128:1284-1293.
    >> Share

  198. COHEN MG, Althouse AD, Arnold RM, Bulls HW, et al
    Hope and advance care planning in advanced cancer: Is there a relationship?
    Cancer. 2022;128:1339-1345.
    >> Share

  199. OWUSU C, Margevicius S, Nock NL, Austin K, et al
    A randomized controlled trial of the effect of supervised exercise on functional outcomes in older African American and non-Hispanic White breast cancer survivors: Are there racial differences in the effects of exercise on functional outcomes?
    Cancer. 2022 Mar 15. doi: 10.1002/cncr.34184.
    >> Share

  200. BALLINGER TJ, Jiang G, Shen F, Miller KD, et al
    Impact of African ancestry on the relationship between body mass index and survival in an early-stage breast cancer trial (ECOG-ACRIN E5103).
    Cancer. 2022 Mar 14. doi: 10.1002/cncr.34173.
    >> Share

  201. RIDGEWAY JL, Jenkins SM, Borah BJ, Suman VJ, et al
    Evaluating educational interventions to increase breast density awareness among Latinas: A randomized trial in a Federally Qualified Health Center.
    Cancer. 2022;128:1038-1047.
    >> Share

    February 2022
  202. OSAKO T, Matsuura M, Yotsumoto D, Takayama S, et al
    A prediction model for early systemic recurrence in breast cancer using a molecular diagnostic analysis of sentinel lymph nodes: A large-scale, multicenter cohort study.
    Cancer. 2022 Feb 28. doi: 10.1002/cncr.34144.
    >> Share

  203. POTERALA JE, Wisinski KB
    Abbreviated endocrine therapy duration for low estrogen receptor-positive breast cancer: The counter to extended endocrine therapy.
    Cancer. 2022 Feb 25. doi: 10.1002/cncr.34158.
    >> Share

  204. CAI YW, Shao ZM, Yu KD
    De-escalation of five-year adjuvant endocrine therapy in patients with estrogen receptor-low positive (immunohistochemistry staining 1%-10%) breast cancer: Propensity-matched analysis from a prospectively maintained cohort.
    Cancer. 2022 Feb 25. doi: 10.1002/cncr.34155.
    >> Share

  205. O'ROURKE K
    Cutaneous beta-HPV may predict cutaneous squamous cell carcinoma.
    Cancer. 2022;128:646.
    >> Share

  206. LU E, Hatchell KE, Nielsen SM, Esplin ED, et al
    Fumarate hydratase variant prevalence and manifestations among individuals receiving germline testing.
    Cancer. 2022;128:675-684.
    >> Share

  207. KUMAR S, Usmanova G, Nair TS, Srivastava VK, et al
    Implementation of a large-scale breast cancer early detection program in a resource-constrained setting: real-world experiences from 2 large states in India.
    Cancer. 2022 Feb 8. doi: 10.1002/cncr.34114.
    >> Share

  208. MORRISON SL, Han G, Elenwa F, Vetto JT, et al
    Is the presence of tumor-infiltrating lymphocytes predictive of outcomes in patients with melanoma?
    Cancer. 2022 Feb 1. doi: 10.1002/cncr.34013.
    >> Share

  209. MAMTANI A, Sevilimedu V, Le T, Morrow M, et al
    Is local recurrence higher among patients who downstage to breast conservation after neoadjuvant chemotherapy?
    Cancer. 2022;128:471-478.
    >> Share

    January 2022
  210. TRAMA A, Tittarelli A, Barigelletti G, Botta L, et al
    Excess risk of subsequent malignant neoplasms in adolescent and young adult cancer survivors: Results from the first Italian population-based cohort.
    Cancer. 2022;128:364-372.
    >> Share

  211. MALLA RR, Vasudevaraju P, Vempati RK, Rakshmitha M, et al
    Regulatory T cells: Their role in triple-negative breast cancer progression and metastasis.
    Cancer. 2022 Jan 6. doi: 10.1002/cncr.34084.
    >> Share

  212. ARUN BK, Peterson SK, Sweeney LE, Bluebond RD, et al
    Increasing referral of at-risk women for genetic counseling and BRCA testing using a screening tool in a community breast imaging center.
    Cancer. 2022;128:94-102.
    >> Share

    December 2021
  213. WONG SM, Ajjamada L, Weiss AC, Prakash I, et al
    Clinicopathologic features of breast cancers diagnosed in women treated with prior radiation therapy for Hodgkin lymphoma: Results from a population-based cohort.
    Cancer. 2021 Dec 17. doi: 10.1002/cncr.34065.
    >> Share

  214. DE ROOIJ BH, Oerlemans S, van Deun K, Mols F, et al
    Symptom clusters in 1330 survivors of 7 cancer types from the PROFILES registry: A network analysis.
    Cancer. 2021;127:4665-4674.
    >> Share

  215. CALIP GS, Wade NB, Guadamuz JS, Wang X, et al
    Disparities in cardiovascular disease mortality after breast cancer treatment: Methodological considerations using real-world data.
    Cancer. 2021 Dec 7. doi: 10.1002/cncr.34045.
    >> Share

  216. CONNOR AE, Kaur M, Sheng JY, Hayes JH, et al
    Racial disparities in mortality outcomes among women diagnosed with breast cancer in Maryland: Impact of cardiovascular disease and clinical characteristics.
    Cancer. 2021 Dec 7. doi: 10.1002/cncr.33889.
    >> Share

  217. TESCH ME, Speers C, Diocee RM, Gondara L, et al
    Impact of TAILORx on chemotherapy prescribing and 21-gene recurrence score-guided treatment costs in a population-based cohort of patients with breast cancer.
    Cancer. 2021 Dec 2. doi: 10.1002/cncr.33982.
    >> Share

  218. CADET T, Pinheiro A, Karamourtopoulos M, Jacobson AR, et al
    Effects by educational attainment of a mammography screening patient decision aid for women aged 75 years and older.
    Cancer. 2021;127:4455-4463.
    >> Share

    November 2021
  219. PHILLIPS SM, Penedo FJ, Collins LM, Solk P, et al
    Optimization of a technology-supported physical activity promotion intervention for breast cancer survivors: Results from Fit2Thrive.
    Cancer. 2021 Nov 23. doi: 10.1002/cncr.34012.
    >> Share

  220. JAVIER-DESLOGES J, Nelson TJ, Murphy JD, McKay RR, et al
    Disparities and trends in the participation of minorities, women, and the elderly in breast, colorectal, lung, and prostate cancer clinical trials.
    Cancer. 2021 Nov 22. doi: 10.1002/cncr.33991.
    >> Share

  221. YU AYL, Thomas SM, DiLalla GD, Greenup RA, et al
    Disease characteristics and mortality among Asian women with breast cancer.
    Cancer. 2021 Nov 18. doi: 10.1002/cncr.34015.
    >> Share

  222. HAY A
    Pricing transparency among several needs for patients with high-risk breast cancer.
    Cancer. 2021;127:4122-4123.
    >> Share

  223. LEWIS DR, Siembida EJ, Seibel NL, Smith AW, et al
    Survival outcomes for cancer types with the highest death rates for adolescents and young adults, 1975-2016.
    Cancer. 2021;127:4277-4286.
    >> Share

  224. KAUR M, Joshu CE, Visvanathan K, Connor AE, et al
    Trends in breast cancer incidence rates by race/ethnicity: Patterns by stage, socioeconomic position, and geography in the United States, 1999-2017.
    Cancer. 2021 Nov 3. doi: 10.1002/cncr.34008.
    >> Share

  225. SEEWALDT VL, Bernstein L
    Reply to Corrections: Breast cancer screening guidelines for young women of color.
    Cancer. 2021 Nov 3. doi: 10.1002/cncr.33989.
    >> Share

  226. GORDON PB, Berg WA
    Corrections: Breast cancer screening guidelines for young women of color.
    Cancer. 2021 Nov 3. doi: 10.1002/cncr.33988.
    >> Share

  227. LEUPIN N, Zinzani PL, Morschhauser F, Dalle S, et al
    Cusatuzumab for treatment of CD70-positive relapsed or refractory cutaneous T-cell lymphoma.
    Cancer. 2021 Nov 2. doi: 10.1002/cncr.34005.
    >> Share

  228. IP EH, Saldana S, Miller KD, Carlos RC, et al
    Tolerability of bevacizumab and chemotherapy in a phase 3 clinical trial with human epidermal growth factor receptor 2-negative breast cancer: A trajectory analysis of adverse events.
    Cancer. 2021 Nov 2. doi: 10.1002/cncr.33992.
    >> Share

  229. PATEL AB, Farooq S, Welborn M, Amaria RN, et al
    Cutaneous adverse events in 155 patients with metastatic melanoma consecutively treated with anti-CTLA4 and anti-PD1 combination immunotherapy: Incidence, management, and clinical benefit.
    Cancer. 2021 Nov 1. doi: 10.1002/cncr.34004.
    >> Share

  230. DILLER ML, Master VA
    Integrative surgical oncology: A model of acute integrative oncology.
    Cancer. 2021;127:3929-3938.
    >> Share

    October 2021
  231. NIERENGARTEN MB
    Higher mortality risk in African American women with triple-negative breast cancer.
    Cancer. 2021;127:3712-3713.
    >> Share

  232. WEISS MC, Hibbs JE, Buckley ME, Danese SR, et al
    A Coala-T-Cannabis Survey Study of breast cancer patients' use of cannabis before, during, and after treatment.
    Cancer. 2021 Oct 12. doi: 10.1002/cncr.33906.
    >> Share

  233. MURUGAPPAN MN, King-Kallimanis BL, Mangir C, Howie L, et al
    Floor and ceiling effects in the EORTC QLQ-C30 Physical Functioning Subscale among patients with advanced or metastatic breast cancer.
    Cancer. 2021 Oct 11. doi: 10.1002/cncr.33959.
    >> Share

  234. JATOI I, Kunkler IH
    Omission of sentinel node biopsy for breast cancer: Historical context and future perspectives on a modern controversy.
    Cancer. 2021 Oct 6. doi: 10.1002/cncr.33960.
    >> Share

  235. SCHAPIRA L, Zheng Y, Gelber SI, Poorvu P, et al
    Trajectories of fear of cancer recurrence in young breast cancer survivors.
    Cancer. 2021 Oct 6. doi: 10.1002/cncr.33921.
    >> Share

  236. GARCIA SF, Gray RJ, Sparano JA, Tevaarwerk AJ, et al
    Fatigue and endocrine symptoms among women with early breast cancer randomized to endocrine versus chemoendocrine therapy: Results from the TAILORx patient-reported outcomes substudy.
    Cancer. 2021 Oct 6. doi: 10.1002/cncr.33939.
    >> Share

  237. BRUNELLE CL, Ag AG
    The important role of nighttime compression in breast cancer-related lymphedema treatment.
    Cancer. 2021 Oct 6. doi: 10.1002/cncr.33942.
    >> Share

  238. MCNEELY ML, Dolgoy ND, Rafn BS, Ghosh S, et al
    Nighttime compression supports improved self-management of breast cancer-related lymphedema: A multicenter randomized controlled trial.
    Cancer. 2021 Oct 6. doi: 10.1002/cncr.33943.
    >> Share

  239. FALKSON CI
    Adjuvant tamoxifen adherence in male patients with breast cancer: An ongoing challenge.
    Cancer. 2021 Oct 1. doi: 10.1002/cncr.33898.
    >> Share

  240. OKE O, Niu J, Chavez-MacGregor M, Zhao H, et al
    Adjuvant tamoxifen adherence in men with early-stage breast cancer.
    Cancer. 2021 Oct 1. doi: 10.1002/cncr.33899.
    >> Share

  241. BERNSTEIN-MOLHO R, Galmor L, Laitman Y, Segev S, et al
    Yield of targeted genotyping for the recurring pathogenic variants in cancer susceptibility genes in a healthy, multiethnic Israeli population.
    Cancer. 2021;127:3599-3604.
    >> Share

    September 2021
  242. TAMI-MAURY IM, Liao Y, Rangel ML, Gatus LA, et al
    Active living after cancer: Adaptation and evaluation of a community-based physical activity program for minority and medically underserved breast cancer survivors.
    Cancer. 2021 Sep 23. doi: 10.1002/cncr.33904.
    >> Share

  243. NIERENGARTEN MB
    Trio of mammography studies demonstrate enhanced screening effectiveness: Recent research on the use of adjunctive technologies and expanded-age screening provides promising results for women with dense breasts.
    Cancer. 2021;127:3279-3280.
    >> Share

  244. PLASCAK JJ, Rundle AG, Xu X, Mooney SJ, et al
    Associations between neighborhood disinvestment and breast cancer outcomes within a populous state registry.
    Cancer. 2021 Sep 8. doi: 10.1002/cncr.33900.
    >> Share

  245. KOTSOPOULOS J, Kim SJ, Armel S, Bordeleau L, et al
    An evaluation of memory and attention in BRCA mutation carriers using an online cognitive assessment tool.
    Cancer. 2021;127:3183-3193.
    >> Share

    August 2021
  246. FEDEWA SA, Cotter MM, Wehling KA, Wysocki K, et al
    Changes in breast cancer screening rates among 32 community health centers during the COVID-19 pandemic.
    Cancer. 2021 Aug 26. doi: 10.1002/cncr.33859.
    >> Share

  247. HENDRICK RE, Monticciolo DL, Biggs KW, Malak SF, et al
    Age distributions of breast cancer diagnosis and mortality by race and ethnicity in US Women.
    Cancer. 2021 Aug 24. doi: 10.1002/cncr.33846.
    >> Share

  248. SEEWALDT VL, Bernstein L
    The perils of generalization: Rethinking breast cancer screening guidelines for young women of color.
    Cancer. 2021 Aug 24. doi: 10.1002/cncr.33840.
    >> Share

  249. YAFFE MJ
    Looking at breast cancer through the ethnic and racial lens-one size definitely does not fit all.
    Cancer. 2021 Aug 24. doi: 10.1002/cncr.33841.
    >> Share

  250. HENDERSON V, Ganschow P, Wang C, Hoskins KF, et al
    Population screening to identify women at risk for hereditary breast cancer syndromes: The path forward or the road not taken?
    Cancer. 2021 Aug 23. doi: 10.1002/cncr.33867.
    >> Share

  251. AOKI RF, Uong SP, Gomez SL, Alexeeff SE, et al
    Individual- and neighborhood-level socioeconomic status and risk of aggressive breast cancer subtypes in a pooled cohort of women from Kaiser Permanente Northern California.
    Cancer. 2021 Aug 20. doi: 10.1002/cncr.33861.
    >> Share

  252. NYROP KA, O'Hare EA, Teal R, Stein K, et al
    Person-centered communication about weight and weight management: Focus group discussions in a diverse sample of women with nonmetastatic breast cancer and obesity.
    Cancer. 2021 Aug 10. doi: 10.1002/cncr.33843.
    >> Share

  253. WOLDEAMANUEL YW, Blayney DW, Jo B, Fisher SE, et al
    Headache outcomes of a sleep behavioral intervention in breast cancer survivors: Secondary analysis of a randomized clinical trial.
    Cancer. 2021 Aug 6. doi: 10.1002/cncr.33844.
    >> Share

  254. NOWAKOWSKA MK, Lei X, Thompson MT, Shaitelman SF, et al
    Association of statin use with clinical outcomes in patients with triple-negative breast cancer.
    Cancer. 2021 Aug 3. doi: 10.1002/cncr.33797.
    >> Share

  255. PRINTZ C
    Mindfulness meditation helps younger breast cancer survivors.
    Cancer. 2021;127:2607.
    >> Share

    July 2021
  256. ROBERTS SA, Gillespie TC, Shui AM, Brunelle CL, et al
    Weight loss does not decrease risk of breast cancer-related arm lymphedema.
    Cancer. 2021 Jul 27. doi: 10.1002/cncr.33819.
    >> Share

  257. ZHAO F, Henderson TO, Cipriano TM, Copley BL, et al
    The impact of coronavirus disease 2019 on the quality of life and treatment disruption of patients with breast cancer in a multiethnic cohort.
    Cancer. 2021 Jul 22. doi: 10.1002/cncr.33798.
    >> Share

  258. POTEAT TC, Adams MA, Malone J, Geffen S, et al
    Delays in breast cancer care by race and sexual orientation: Results from a national survey with diverse women in the United States.
    Cancer. 2021 Jul 19. doi: 10.1002/cncr.33629.
    >> Share

  259. FAN Q, Yao XA, Han X
    Spatial variation and disparity in female breast cancer relative survival in the United States.
    Cancer. 2021 Jul 15. doi: 10.1002/cncr.33801.
    >> Share

  260. KURIAN AW, Hughes E, Simmons T, Bernhisel R, et al
    Performance of the IBIS/Tyrer-Cuzick model of breast cancer risk by race and ethnicity in the Women's Health Initiative.
    Cancer. 2021 Jul 6. doi: 10.1002/cncr.33767.
    >> Share

    June 2021
  261. GREER AC, Lanes A, Poorvu PD, Kennedy P, et al
    The impact of fertility preservation on the timing of breast cancer treatment, recurrence, and survival.
    Cancer. 2021 Jun 23. doi: 10.1002/cncr.33601.
    >> Share

  262. BROWN JC, Sarwer DB, Troxel AB, Sturgeon K, et al
    A randomized trial of exercise and diet on health-related quality of life in survivors of breast cancer with overweight or obesity.
    Cancer. 2021 Jun 23. doi: 10.1002/cncr.33752.
    >> Share

  263. LYNCE F, Blackburn MJ, Zhuo R, Gallagher C, et al
    Hematologic safety of palbociclib in combination with endocrine therapy in patients with benign ethnic neutropenia and advanced breast cancer.
    Cancer. 2021 Jun 22. doi: 10.1002/cncr.33620.
    >> Share

  264. MAKHNOON S, Tran G, Levin B, Mattie KD, et al
    Uptake of cancer risk management strategies among women who undergo cascade genetic testing for breast cancer susceptibility genes.
    Cancer. 2021 Jun 22. doi: 10.1002/cncr.33668.
    >> Share

  265. PRINTZ C
    Less-educated minority women have less 3-D mammography access.
    Cancer. 2021;127:1953.
    >> Share

  266. PRINTZ C
    Female breast cancer most commonly diagnosed cancer globally.
    Cancer. 2021;127:1952-1953.
    >> Share

  267. PRINTZ C
    Some patients with postmenopausal breast cancer can avoid adjuvant chemotherapy: Data indicate that some postmenopausal women with breast cancer can safely skip adjuvant chemotherapy.
    Cancer. 2021;127:1951-1952.
    >> Share

  268. HENSING WL, Poplack SP, Herman CR, Sutcliffe S, et al
    Racial differences in no-show rates for screening mammography.
    Cancer. 2021;127:1857-1863.
    >> Share

  269. WHITE DP, Kurian AW, Stevens JL, Liu B, et al
    Receipt of guideline-concordant care among young adult women with breast cancer.
    Cancer. 2021 Jun 1. doi: 10.1002/cncr.33652.
    >> Share

  270. MCCARTHY AM, Ehsan S, Appel S, Welch M, et al
    Risk factors for an advanced breast cancer diagnosis within 2 years of a negative mammogram.
    Cancer. 2021 Jun 1. doi: 10.1002/cncr.33661.
    >> Share

    May 2021
  271. DHAKAL A, Falkson C, O'Regan RM
    Adjuvant cyclin-dependent kinase 4/6 inhibition in hormone receptor-positive breast cancer: One Monarch to rule them all?
    Cancer. 2021 May 28. doi: 10.1002/cncr.33650.
    >> Share

  272. SUNG H, Freedman RA, Siegel RL, Hyun N, et al
    Risks of subsequent primary cancers among breast cancer survivors according to hormone receptor status.
    Cancer. 2021 May 18. doi: 10.1002/cncr.33602.
    >> Share

  273. PRINTZ C
    Immune Factors Tied to Aggressive Breast Cancers in Black Patients.
    Cancer. 2021;127:1546.
    >> Share

  274. MATTHYS MB, Dempsey AM, Melisko ME, Dreher N, et al
    Incorporation of Patient-Reported Outcomes Measurement Information System to assess quality of life among patients with breast cancer initiating care at an academic center.
    Cancer. 2021 May 6. doi: 10.1002/cncr.33496.
    >> Share

  275. FARVID MS, Spence ND, Rosner BA, Chen WY, et al
    Consumption of sugar-sweetened and artificially sweetened beverages and breast cancer survival.
    Cancer. 2021 May 4. doi: 10.1002/cncr.33461.
    >> Share

  276. PRINTZ C
    First Person Profile: Cheryl Willman, MD: As director and CEO of the University of New Mexico Comprehensive Cancer Center, Dr. Willman has led major health equity initiatives while making pioneering discoveries in precision medicine.
    Cancer. 2021;127:1357-1358.
    >> Share

    April 2021
  277. DI MEGLIO A, Gbenou AS, Martin E, Pistilli B, et al
    Unhealthy behaviors after breast cancer: Capitalizing on a teachable moment to promote lifestyle improvements.
    Cancer. 2021 Apr 22. doi: 10.1002/cncr.33565.
    >> Share

  278. SELLA T, Poorvu PD, Ruddy KJ, Gelber SI, et al
    Impact of fertility concerns on endocrine therapy decisions in young breast cancer survivors.
    Cancer. 2021 Apr 22. doi: 10.1002/cncr.33596.
    >> Share

  279. TAYLOR CE, Meisel JL
    We have to talk about it: Bringing fertility into the conversation for young women with breast cancer.
    Cancer. 2021 Apr 22. doi: 10.1002/cncr.33595.
    >> Share

  280. ADRADA BE, Candelaria R, Moulder S, Thompson A, et al
    Early ultrasound evaluation identifies excellent responders to neoadjuvant systemic therapy among patients with triple-negative breast cancer.
    Cancer. 2021 Apr 20. doi: 10.1002/cncr.33604.
    >> Share

  281. PRINTZ C
    Updated American Cancer Society HPV Vaccine Guideline Seeks to Reinforce Key Messages: New recommendations emphasize the importance of routinely offering the vaccine at the ages of 9 to 12 years.
    Cancer. 2021;127:1169-1170.
    >> Share

  282. TAIT SD, Ren Y, Horton CC, Oshima SM, et al
    Characterizing participants in the North Carolina Breast and Cervical Cancer Control Program: A retrospective review of 90,000 women.
    Cancer. 2021 Apr 7. doi: 10.1002/cncr.33473.
    >> Share

  283. STANGL S, Rauch S, Rauh J, Meyer M, et al
    Disparities in accessibility to evidence-based breast cancer care facilities by rural and urban areas in Bavaria, Germany.
    Cancer. 2021 Apr 7. doi: 10.1002/cncr.33493.
    >> Share

  284. CORSO G, Maisonneuve P, Veronesi P
    Impact of radiation and hormonal therapy on the locoregional recurrence of elderly breast cancer: Are these necessary after breast-conserving surgery?
    Cancer. 2021 Apr 1. doi: 10.1002/cncr.33550.
    >> Share

  285. TRINGALE KR, Berger ER, Heerdt AS, Braunstein LZ, et al
    Reply to Impact of radiation and hormonal therapy on the locoregional recurrence of elderly breast cancer: Are these necessary after breast-conserving surgery?
    Cancer. 2021 Apr 1. doi: 10.1002/cncr.33551.
    >> Share

  286. HENDERSON V, Chukwudozie IB, Comer-Hagans D, Coffey V, et al
    Development of a culturally sensitive narrative intervention to promote genetic counseling among African American women at risk for hereditary breast cancer.
    Cancer. 2021 Apr 1. doi: 10.1002/cncr.33525.
    >> Share

  287. CONNOR AE, Schmaltz CL, Jackson-Thompson J, Visvanathan K, et al
    Comorbidities and the risk of cardiovascular disease mortality among racially diverse patients with breast cancer.
    Cancer. 2021 Apr 1. doi: 10.1002/cncr.33530.
    >> Share

    March 2021
  288. TAMIRISA N, Lin H, Shen Y, Shaitelman SF, et al
    Impact of adjuvant endocrine therapy in older patients with comorbidities and estrogen receptor-positive, node-negative breast cancer-a National Cancer Database analysis.
    Cancer. 2021 Mar 18. doi: 10.1002/cncr.33489.
    >> Share

  289. FAN R, Chen Y, Nechuta S, Cai H, et al
    Prediction models for breast cancer prognosis among Asian women.
    Cancer. 2021 Mar 11. doi: 10.1002/cncr.33425.
    >> Share

    February 2021
  290. EMERSON MA, Achacoso NS, Benefield HC, Troester MA, et al
    Initiation and adherence to adjuvant endocrine therapy among urban, insured American Indian/Alaska Native breast cancer survivors.
    Cancer. 2021 Feb 23. doi: 10.1002/cncr.33423.
    >> Share

  291. MUKAMA T, Kharazmi E, Sundquist K, Sundquist J, et al
    Risk-adapted starting age of breast cancer screening in women with a family history of ovarian or other cancers: A nationwide cohort study.
    Cancer. 2021 Feb 23. doi: 10.1002/cncr.33456.
    >> Share

  292. BOWER JE, Ganz PA, Irwin MR, Cole SW, et al
    Do all patients with cancer experience fatigue? a longitudinal study of fatigue trajectories in women with breast cancer.
    Cancer. 2021 Feb 19. doi: 10.1002/cncr.33327.
    >> Share

  293. OBENG-GYASI S, Timsina LR, Bhattacharyya O, Fisher CS, et al
    Bankruptcy among insured patients with surgical breast cancer: Who is at risk?
    Cancer. 2021 Feb 19. doi: 10.1002/cncr.33468.
    >> Share

  294. OWUSU C, Nock NL, Feuntes V, Margevicius S, et al
    IMPROVE, a community-based exercise intervention versus support group to improve functional and health outcomes among older African American and Non-Hispanic White breast cancer survivors from diverse socioeconomic backgrounds: Recruitment strategies
    Cancer. 2021 Feb 4. doi: 10.1002/cncr.33430.
    >> Share

  295. LEE RT, Kwon N, Wu J, To C, et al
    Prevalence of potential interactions of medications, including herbs and supplements, before, during, and after chemotherapy in patients with breast and prostate cancer.
    Cancer. 2021 Feb 1. doi: 10.1002/cncr.33324.
    >> Share

    January 2021
  296. REEDER-HAYES KE, Mayer SE, Lund JL
    Adherence to endocrine therapy including ovarian suppression: A large observational cohort study of US women with early breast cancer.
    Cancer. 2021 Jan 28. doi: 10.1002/cncr.33367.
    >> Share

  297. TRINGALE KR, Berger ER, Sevilimedu V, Wen HY, et al
    Breast conservation among older patients with early-stage breast cancer: Locoregional recurrence following adjuvant radiation or hormonal therapy.
    Cancer. 2021 Jan 26. doi: 10.1002/cncr.33422.
    >> Share

  298. YUAN Y, Pan K, Mortimer J, Chlebowski RT, et al
    Metabolic syndrome risk components and mortality after triple-negative breast cancer diagnosis in postmenopausal women in the Women's Health Initiative.
    Cancer. 2021 Jan 21. doi: 10.1002/cncr.33407.
    >> Share

    December 2020
  299. KNAPP GC, Tansley G, Olasehinde O, Wuraola F, et al
    Geospatial access predicts cancer stage at presentation and outcomes for patients with breast cancer in southwest Nigeria: A population-based study.
    Cancer. 2020 Dec 28. doi: 10.1002/cncr.33394.
    >> Share

  300. SHAO D, Zhang H, Cui N, Sun J, et al
    The efficacy and mechanisms of a guided self-help intervention based on mindfulness in patients with breast cancer: A randomized controlled trial.
    Cancer. 2020 Dec 17. doi: 10.1002/cncr.33381.
    >> Share

  301. SEAH DS, Leone JP, Openshaw TH, Scott SM, et al
    Perceptions of patients with early stage breast cancer toward research biopsies.
    Cancer. 2020 Dec 15. doi: 10.1002/cncr.33371.
    >> Share

  302. LEONE JP, Cole BF, Regan MM, Thurlimann B, et al
    Clinical behavior of recurrent hormone receptor-positive breast cancer by adjuvant endocrine therapy within the Breast International Group 1-98 clinical trial.
    Cancer. 2020 Dec 8. doi: 10.1002/cncr.33318.
    >> Share

  303. TAYLOR CE, Meisel JL
    Weighing the influence of race and obesity on outcomes in patients with early-stage breast cancer.
    Cancer. 2020 Dec 7. doi: 10.1002/cncr.33290.
    >> Share

  304. NYROP KA, Damone EM, Deal AM, Carey LA, et al
    Obesity, comorbidities, and treatment selection in Black and White women with early breast cancer.
    Cancer. 2020 Dec 7. doi: 10.1002/cncr.33288.
    >> Share

  305. POORVU PD, Gelber SI, Zheng Y, Ruddy KJ, et al
    Pregnancy after breast cancer: Results from a prospective cohort of young women with breast cancer.
    Cancer. 2020 Dec 1. doi: 10.1002/cncr.33342.
    >> Share

  306. MOHL A, Orban E, Jung AY, Behrens S, et al
    Comorbidity burden in long-term breast cancer survivors compared with a cohort of population-based controls from the MARIE study.
    Cancer. 2020 Dec 1. doi: 10.1002/cncr.33363.
    >> Share

    November 2020
  307. PARK J, Rodriguez JL, O'Brien KM, Nichols HB, et al
    Health-related quality of life outcomes among breast cancer survivors.
    Cancer. 2020 Nov 25. doi: 10.1002/cncr.33348.
    >> Share

  308. NYROP KA, Deal AM, Chen YT, Reeve BB, et al
    Patient-reported symptom severity, interference with daily activities, and adverse events in older and younger women receiving chemotherapy for early breast cancer.
    Cancer. 2020 Nov 20. doi: 10.1002/cncr.33329.
    >> Share

  309. BERRIAN JL, Liu Y, Lian M, Schmaltz CL, et al
    Relationship between insurance status and outcomes for patients with breast cancer in Missouri.
    Cancer. 2020 Nov 17. doi: 10.1002/cncr.33330.
    >> Share

  310. FAYANJU OM, Ren Y, Stashko I, Power S, et al
    Patient-reported causes of distress predict disparities in time to evaluation and time to treatment after breast cancer diagnosis.
    Cancer. 2020 Nov 11. doi: 10.1002/cncr.33310.
    >> Share

  311. DESANTIS CE, Siegel RL
    The importance of comprehensive data and statistical testing in the interpretation of breast cancer incidence trends.
    Cancer. 2020 Nov 10. doi: 10.1002/cncr.33263.
    >> Share

  312. DESAI NV, Yadav S, Batalini F, Couch FJ, et al
    Germline genetic testing in breast cancer: Rationale for the testing of all women diagnosed by the age of 60 years and for risk-based testing of those older than 60 years.
    Cancer. 2020 Nov 4. doi: 10.1002/cncr.33305.
    >> Share

  313. SEEWALDT VL
    Time for action: The Patient Protection and Affordable Care Act Medicaid expansion significantly improves breast cancer care for women in Louisiana.
    Cancer. 2020 Nov 3. doi: 10.1002/cncr.33264.
    >> Share

  314. CHU QD, Li T, Hsieh MC, Yi Y, et al
    Positive impact of the Patient Protection and Affordable Care Act Medicaid expansion on Louisiana women with breast cancer.
    Cancer. 2020 Nov 3. doi: 10.1002/cncr.33265.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016